Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19217808 | METHODS OF USING A GIP/GLP1 CO-AGONIST FOR THERAPY | May 2025 | March 2026 | Allow | 9 | 2 | 1 | Yes | No |
| 19174121 | SEMAGLUTIDE IN MEDICAL THERAPY | April 2025 | December 2025 | Allow | 8 | 2 | 0 | No | No |
| 19023048 | PHARMACEUTICAL COMPOSITIONS COMPRISING NOVEL CYCLIC PEPTIDES | January 2025 | April 2025 | Allow | 3 | 1 | 0 | Yes | No |
| 18820792 | SEMAGLUTIDE IN MEDICAL THERAPY | August 2024 | February 2025 | Allow | 5 | 2 | 0 | No | No |
| 18754189 | CYCLOPHILIN INHIBITORS AND USES THEREOF | June 2024 | September 2025 | Allow | 14 | 1 | 1 | No | No |
| 18724136 | IL-4 DERIVED PEPTIDE FRAGMENTS FOR USE IN THE TREATMENT OF DIABETIC NEPHROPATHY | June 2024 | June 2025 | Allow | 12 | 2 | 0 | No | No |
| 18751723 | NPY2 RECEPTOR AGONISTS | June 2024 | May 2025 | Allow | 11 | 0 | 1 | No | No |
| 18736608 | SEMAGLUTIDE IN MEDICAL THERAPY | June 2024 | January 2025 | Abandon | 7 | 0 | 0 | No | No |
| 18734820 | PEPTIDES, HYDROGEL COMPOSITIONS AND METHODS OF USE THEREOF | June 2024 | July 2025 | Allow | 13 | 1 | 1 | No | No |
| 18666750 | STAPLED AND SPECIFICALLY TARGETED ANTIMICROBIAL PEPTIDE | May 2024 | November 2024 | Allow | 6 | 1 | 1 | No | No |
| 18660504 | NOVEL PEPTIDES | May 2024 | August 2024 | Allow | 3 | 0 | 0 | No | No |
| 18661201 | HUMAN AMYLIN ANALOG POLYPEPTIDES AND METHODS OF USE | May 2024 | October 2025 | Allow | 17 | 1 | 1 | No | No |
| 18639139 | ANTIFUNGAL PROTEIN COMPOSITION | April 2024 | February 2026 | Abandon | 22 | 0 | 1 | No | No |
| 18627757 | COMPOUNDS FOR USE AS APELIN RECEPTOR ANTAGONISTS | April 2024 | September 2025 | Allow | 18 | 1 | 1 | Yes | No |
| 18615134 | METHODS AND COMPOSITIONS FOR TREATING MUCOSAL TISSUE DISORDERS | March 2024 | March 2026 | Allow | 24 | 1 | 1 | No | No |
| 18423020 | ANTI-KRAS-G12D T CELL RECEPTORS | January 2024 | April 2025 | Allow | 15 | 1 | 1 | No | No |
| 18415952 | BIOLOGICAL ACTIVE PEPTIDE FOR IMPROVING ENZYME ACTIVITY OF ACE2 AND APPLICATION THEREOF | January 2024 | January 2025 | Allow | 12 | 2 | 0 | No | No |
| 18540193 | URI Agonist/Vasodilator | December 2023 | February 2026 | Allow | 26 | 3 | 1 | Yes | No |
| 18494623 | SELECTIVE TARGETING OF APOPTOSIS PROTEINS BY STRUCTURALLY-STABILIZED AND/OR CYSTEINE-REACTIVE NOXA PEPTIDES | October 2023 | July 2025 | Allow | 20 | 1 | 1 | No | No |
| 18492612 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | October 2023 | November 2025 | Allow | 24 | 2 | 1 | No | No |
| 18483123 | MODIFIED PEPTIDES AND ASSOCIATED METHODS OF USE | October 2023 | October 2025 | Allow | 24 | 2 | 1 | Yes | No |
| 18476860 | BCL9 PEPTIDES AND VARIANTS THEREOF | September 2023 | July 2025 | Abandon | 22 | 1 | 1 | No | No |
| 18474843 | AGENT FOR PROMOTING ANGIOGENESIS AND METHODS AND USES THEREOF | September 2023 | November 2025 | Abandon | 26 | 0 | 1 | No | No |
| 18471220 | REGENERATIVE POLYPEPTIDES AND USES THEREOF | September 2023 | December 2024 | Abandon | 15 | 2 | 1 | No | No |
| 18363448 | MATERIALS AND METHODS FOR IMPROVING GASTROINTESTINAL FUNCTION | August 2023 | October 2024 | Allow | 15 | 1 | 1 | No | No |
| 18212119 | COMPOSITIONS AND METHODS FOR IMPROVING BRUISING AND REJUVENATING SKIN | June 2023 | September 2024 | Allow | 15 | 2 | 1 | Yes | No |
| 18334309 | INTERLEUKIN-13 BINDING CYCLIC OLIGOPEPTIDES AND METHODS OF USE THEREOF | June 2023 | August 2024 | Allow | 14 | 1 | 1 | No | No |
| 18321472 | IL-2R-BETA-GAMMA BINDING COMPOUNDS | May 2023 | November 2024 | Abandon | 17 | 0 | 1 | No | No |
| 18299600 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | April 2023 | July 2025 | Allow | 28 | 3 | 1 | No | No |
| 18176013 | ALK POLYPEPTIDES AND METHODS OF USE THEREOF | February 2023 | March 2025 | Allow | 25 | 3 | 1 | No | No |
| 18112468 | Ocular Compositions and Methods Thereof | February 2023 | November 2025 | Allow | 32 | 4 | 1 | Yes | No |
| 18170163 | USE OF PAYCS IN REGULATION OF INTESTINAL FLORA, METABOLITES, AND BRAIN NEUROTRANSMITTERS | February 2023 | July 2024 | Allow | 17 | 2 | 1 | No | No |
| 18164297 | NOVEL MUTANT BACTERIORHODOPSIN-LIKE-CHANNELRHODOPSIN ION CHANNEL | February 2023 | January 2026 | Allow | 36 | 5 | 1 | Yes | No |
| 18105752 | FORMULATIONS WITH REDUCED OXIDATION | February 2023 | February 2026 | Abandon | 36 | 4 | 1 | Yes | Yes |
| 18163210 | Regenerative Polypeptides and Uses Thereof | February 2023 | April 2024 | Abandon | 14 | 0 | 1 | No | No |
| 18160513 | TREATMENT OF RESPIRATORY TRACT DISEASES AND INFECTIONS WITH ASCORBIC ACID COMPOSITIONS | January 2023 | June 2025 | Allow | 28 | 1 | 2 | No | No |
| 18100032 | SOLID STATE FORMS OF VOCLOSPORIN | January 2023 | December 2024 | Allow | 23 | 1 | 0 | No | No |
| 18146779 | THERAPEUTIC PEPTIDES | December 2022 | May 2025 | Abandon | 28 | 2 | 1 | No | No |
| 18068641 | NPY2 RECEPTOR AGONISTS | December 2022 | April 2024 | Allow | 15 | 1 | 1 | No | No |
| 18077902 | SYNTHESIS OF ECHINOCANDIN ANTIFUNGAL AGENT | December 2022 | August 2024 | Allow | 21 | 1 | 1 | No | No |
| 18076759 | PROMOTING TRAINED IMMUNITY WITH THERAPEUTIC NANOBIOLOGIC COMPOSITIONS | December 2022 | December 2024 | Abandon | 24 | 1 | 1 | No | No |
| 17991219 | CCN3 AND CCN3 PEPTIDES AND ANALOGS THEREOF FOR THERAPEUTIC USE | November 2022 | February 2024 | Allow | 15 | 1 | 1 | No | No |
| 17998366 | PEPTIDE FOR USE IN THE PREVENTION AND/OR TREATMENT OF A DISEASE CAUSED BY A VIRUS AFFECTING THE RESPIRATORY TRACT | November 2022 | November 2025 | Allow | 36 | 1 | 0 | No | No |
| 18054261 | MACROCYCLIC POLYPEPTIDES | November 2022 | February 2024 | Abandon | 16 | 0 | 1 | No | No |
| 17998411 | JNK3 INHIBITORY PEPTIDES | November 2022 | March 2026 | Allow | 40 | 2 | 0 | No | No |
| 17981446 | Compositions and Method of Use for Hair Straightening and Shaping | November 2022 | January 2025 | Allow | 27 | 1 | 1 | No | No |
| 17997507 | PD-L1 BINDING PEPTIDES | October 2022 | January 2026 | Allow | 39 | 1 | 0 | No | No |
| 17920149 | ANTIBACTERIAL PROTEIN CDL200 HAVING LYTIC ACTIVITY AGAINST CLOSTRIDIOIDES DIFFICILE | October 2022 | October 2025 | Allow | 35 | 1 | 0 | No | No |
| 17965739 | CDKN2A COMPANION DIAGNOSTIC FOR BLADDER CANCER INTERFERON THERAPY | October 2022 | August 2024 | Allow | 22 | 2 | 1 | No | No |
| 17938624 | FORMULATIONS AND METHODS OF USE FOR ALPHA CONNEXIN C-TERMINAL (ACT) PEPTIDES | October 2022 | June 2024 | Allow | 20 | 2 | 1 | No | No |
| 17916778 | LIQUID PHARMACEUTICAL FORMULATIONS POLYETHYLENE GLYCOL-BASED PRODRUGS OF ADRENOMEDULLIN AND USE | October 2022 | January 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17936956 | Beta-Arrestin Effectors and Compositions and Methods of Use Thereof | September 2022 | March 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17935726 | CYCLIC POLYPEPTIDES FOR PCSK9 INHIBITION | September 2022 | January 2024 | Allow | 16 | 1 | 1 | No | No |
| 17946071 | CYCLOPHILIN INHIBITORS AND USES THEREOF | September 2022 | April 2024 | Allow | 19 | 4 | 1 | No | No |
| 17906403 | PEPTIDE SYNTHESIS AND SYSTEM THEREOF | September 2022 | December 2025 | Allow | 39 | 1 | 1 | Yes | No |
| 17911277 | PEPTIDE ANALOGS AND USE OF SAME IN TREATING DISEASES, DISORDERS OR CONDITIONS ASSOCIATED WITH MUTANT P53 PROTEIN | September 2022 | March 2026 | Abandon | 42 | 0 | 1 | No | No |
| 17943955 | SYNTHETIC PLATELETS | September 2022 | July 2024 | Allow | 23 | 1 | 1 | No | No |
| 17910467 | NORRIN REGULATION OF PLASMALEMMA VESICLE-ASSOCIATED PROTEIN AND USE TO TREAT MACULAR DEGENERATION | September 2022 | January 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17899634 | CELL-PENETRATING PEPTIDE DIMERS, METHOD FOR PREPARING THE SAME, AND CARGO DELIVERY SYSTEM USING THE SAME | August 2022 | July 2024 | Abandon | 23 | 2 | 1 | No | No |
| 17898220 | CYCLIC POLYPEPTIDES FOR PCSK9 INHIBITION | August 2022 | November 2023 | Allow | 14 | 1 | 1 | No | No |
| 17820243 | PROTEINS WITH CARDIOPROTECTIVE ACTIVITY | August 2022 | August 2024 | Allow | 24 | 3 | 1 | Yes | No |
| 17817084 | Therapeutic Agent for Psoriasis | August 2022 | March 2025 | Allow | 32 | 2 | 1 | No | No |
| 17760081 | TARGETED PLASMA PROTEIN DEGRADATION | August 2022 | January 2026 | Allow | 42 | 2 | 1 | No | No |
| 17879143 | METHODS FOR THE PREVENTION AND TREATMENT OF BURN INJURIES AND SECONDARY COMPLICATIONS | August 2022 | February 2025 | Abandon | 31 | 2 | 1 | No | No |
| 17795129 | COMPOSITIONS INCLUDING ANTIMICROBIAL POLYMER- PEPTIDE CONJUGATES AND USES THEREOF | July 2022 | February 2026 | Allow | 42 | 2 | 1 | No | No |
| 17864685 | COMPOSITION OF FISH SKIN COLLAGEN PEPTIDES AND USE THEREOF AS A DRUG | July 2022 | July 2024 | Allow | 24 | 3 | 1 | Yes | No |
| 17811470 | AGENT FOR PROMOTING ANGIOGENESIS AND METHODS AND USES THEREOF | July 2022 | November 2023 | Abandon | 17 | 0 | 1 | No | No |
| 17853839 | Technology for Modulating Targeting Chimeras Induced by Cell-Penetrating Peptide and Application Thereof | June 2022 | July 2024 | Abandon | 24 | 1 | 1 | No | No |
| 17851959 | N-TERMINAL CAPPING MODULES OF ANKYRIN REPEAT DOMAINS | June 2022 | January 2024 | Allow | 18 | 2 | 1 | Yes | No |
| 17842953 | GhR-BINDING PEPTIDE AND COMPOSITION COMPRISING SAME | June 2022 | May 2025 | Allow | 35 | 5 | 1 | No | No |
| 17843748 | Regenerative Polypeptides and Uses Thereof | June 2022 | March 2025 | Allow | 33 | 1 | 1 | No | No |
| 17838766 | METHODS FOR REDUCING RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED THEREWITH | June 2022 | May 2025 | Abandon | 35 | 3 | 1 | No | No |
| 17830565 | NOVEL AMPHIPHILIC PEPTIDE CHAPERONES AND METHODS OF USE | June 2022 | October 2023 | Allow | 16 | 2 | 1 | No | No |
| 17781022 | POLYPEPTIDE TAG AND APPLICATION THEREOF IN IN VITRO PROTEIN SYNTHESIS | May 2022 | February 2026 | Allow | 44 | 2 | 1 | Yes | No |
| 17824621 | AUTOPHAGY AS A THERAPEUTIC TARGET FOR INTRACRANIAL ANEURYSM | May 2022 | June 2024 | Allow | 25 | 4 | 1 | No | Yes |
| 17778785 | A NEW ANTIBIOTIC SELECTIVELY KILLS GRAM-NEGATIVE PATHOGENS | May 2022 | January 2026 | Allow | 44 | 2 | 1 | No | No |
| 17743321 | Polypeptides Related to HMGB1 Useful for Promoting Tissue Regeneration, Compositions Comprising Same, and Uses Thereof | May 2022 | January 2026 | Allow | 44 | 1 | 1 | No | No |
| 17737714 | NOVEL PEPTIDE | May 2022 | November 2023 | Allow | 18 | 1 | 1 | No | No |
| 17660969 | ANTIFUNGAL PROTEIN COMPOSITION | April 2022 | September 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17771334 | METHODS FOR TREATING PATIENTS HAVING CFH MUTATIONS WITH RECOMBINANT CFH PROTEINS | April 2022 | December 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17724913 | POLYMER AGONISTS OF MU OPIOID RECEPTORS | April 2022 | July 2024 | Allow | 27 | 2 | 1 | No | No |
| 17724927 | Methods and Compositions for Treatment of Antibiotic-Resistant Bacterial Infections | April 2022 | March 2025 | Allow | 35 | 5 | 1 | Yes | Yes |
| 17767550 | CYCLIC PEPTIDE HAVING CTLA-4 INHIBITORY ACTIVITY AND USE THEREOF | April 2022 | November 2025 | Allow | 43 | 2 | 0 | No | No |
| 17658129 | INSECTICIDAL PROTEINS AND METHODS FOR THEIR USE | April 2022 | March 2025 | Abandon | 35 | 4 | 1 | No | No |
| 17703770 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | March 2022 | December 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17701561 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LISTERIA VIRULENCE | March 2022 | May 2024 | Allow | 26 | 3 | 1 | Yes | No |
| 17639082 | SYNTHETIC ANTIMICROBIAL PEPTIDES | February 2022 | October 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17633146 | COMPOSITIONS AND METHODS FOR TREATMENT | February 2022 | June 2025 | Allow | 41 | 1 | 1 | No | No |
| 17586196 | CONDITIONALLY IMMORTALIZED LONG-TERM STEM CELLS AND METHODS OF MAKING AND USING SUCH CELLS | January 2022 | November 2023 | Abandon | 22 | 0 | 1 | No | No |
| 17579237 | CONJUGATION OF MCR1 LIGAND WITH CYTOTOXIC DRUGS FOR TREATING SKIN CANCER | January 2022 | June 2025 | Allow | 41 | 1 | 1 | No | No |
| 17627378 | NOVEL INHIBITORS OF KALLIKREIN PROTEASES AND USES THEREOF | January 2022 | November 2025 | Abandon | 46 | 2 | 1 | No | No |
| 17569129 | ZWITTERIONIC POLYMER-INSULIN COMPOSITIONS AND RELATED METHODS | January 2022 | November 2024 | Allow | 34 | 2 | 1 | No | Yes |
| 17568411 | DUAL IL-2R AND IL-7R BINDING COMPOUNDS | January 2022 | October 2024 | Abandon | 34 | 3 | 1 | No | No |
| 17555392 | COMPOSITIONS AND METHOD OF USE FOR HAIR STRAIGHTENING AND SHAPING | December 2021 | October 2022 | Allow | 10 | 2 | 1 | No | No |
| 17550306 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISORDERS AND ALZHEIMER'S DISEASE AND IMPROVING NORMAL MEMORY | December 2021 | October 2023 | Abandon | 22 | 0 | 1 | No | No |
| 17549579 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | December 2021 | September 2025 | Allow | 45 | 5 | 1 | Yes | No |
| 17546177 | RATIONALLY DESIGNED ANTIVIRAL COMPOUNDS THAT INHIBIT SARS-CoV-2 AND THEIR METHODS OF USE THEREOF | December 2021 | August 2023 | Abandon | 20 | 1 | 1 | No | No |
| 17545870 | TREATMENT OF PATIENTS WITH SEVERE VON WILLEBRAND DISEASE UNDERGOING ELECTIVE SURGERY BY ADMINISTRATION OF RECOMBINANT VWF | December 2021 | March 2026 | Allow | 51 | 5 | 1 | No | Yes |
| 17543464 | Selective and Noncovalent Inhibitors of Oncogenic RAS Mutants | December 2021 | March 2024 | Allow | 27 | 3 | 1 | Yes | No |
| 17541619 | ANTI-KRAS-G12D T CELL RECEPTORS | December 2021 | July 2023 | Allow | 20 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner COFFA, SERGIO.
With a 14.3% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner COFFA, SERGIO works in Art Unit 1658 and has examined 343 patent applications in our dataset. With an allowance rate of 57.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.
Examiner COFFA, SERGIO's allowance rate of 57.1% places them in the 17% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by COFFA, SERGIO receive 2.70 office actions before reaching final disposition. This places the examiner in the 79% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by COFFA, SERGIO is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +30.9% benefit to allowance rate for applications examined by COFFA, SERGIO. This interview benefit is in the 79% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 14.4% of applications are subsequently allowed. This success rate is in the 10% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 37.2% of cases where such amendments are filed. This entry rate is in the 56% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 122.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 83% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 76.7% of appeals filed. This is in the 68% percentile among all examiners. Of these withdrawals, 69.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 89.7% are granted (fully or in part). This grant rate is in the 88% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.3% of allowed cases (in the 55% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.0% of allowed cases (in the 61% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.